136 related articles for article (PubMed ID: 29960002)
1. Expression of cytochrome P450 epoxygenases and soluble epoxide hydrolase is regulated by hypolipidemic drugs in dose-dependent manner.
Cizkova K
Toxicol Appl Pharmacol; 2018 Sep; 355():156-163. PubMed ID: 29960002
[TBL] [Abstract][Full Text] [Related]
2. Time-dependent expression pattern of cytochrome P450 epoxygenases and soluble epoxide hydrolase in normal human placenta.
Cizkova K; Tauber Z
Acta Histochem; 2018 Aug; 120(6):513-519. PubMed ID: 29908721
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor ɑ (PPARɑ)-cytochrome P450 epoxygenases-soluble epoxide hydrolase axis in ER + PR + HER2- breast cancer.
Tauber Z; Koleckova M; Cizkova K
Med Mol Morphol; 2020 Sep; 53(3):141-148. PubMed ID: 31823010
[TBL] [Abstract][Full Text] [Related]
4. Increased epoxyeicosatrienoic acids may be part of a protective mechanism in human ulcerative colitis, with increased CYP2J2 and reduced soluble epoxide hydrolase expression.
Qiu YE; Qin J; Luo Y; Qin SL; Mu YF; Cun R; Jiang HL; Chen JJ; Yu MH; Zhong M
Prostaglandins Other Lipid Mediat; 2018 May; 136():9-14. PubMed ID: 29580941
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha.
Ng VY; Huang Y; Reddy LM; Falck JR; Lin ET; Kroetz DL
Drug Metab Dispos; 2007 Jul; 35(7):1126-34. PubMed ID: 17431031
[TBL] [Abstract][Full Text] [Related]
6. The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases.
Xu X; Zhang XA; Wang DW
Adv Drug Deliv Rev; 2011 Jul; 63(8):597-609. PubMed ID: 21477627
[TBL] [Abstract][Full Text] [Related]
7. Elevated 14,15- epoxyeicosatrienoic acid by increasing of cytochrome P450 2C8, 2C9 and 2J2 and decreasing of soluble epoxide hydrolase associated with aggressiveness of human breast cancer.
Wei X; Zhang D; Dou X; Niu N; Huang W; Bai J; Zhang G
BMC Cancer; 2014 Nov; 14():841. PubMed ID: 25406731
[TBL] [Abstract][Full Text] [Related]
8. Acute mercury toxicity modulates cytochrome P450, soluble epoxide hydrolase and their associated arachidonic acid metabolites in C57Bl/6 mouse heart.
Amara IE; Elshenawy OH; Abdelrady M; El-Kadi AO
Toxicol Lett; 2014 Apr; 226(1):53-62. PubMed ID: 24472606
[TBL] [Abstract][Full Text] [Related]
9. Increased epoxyeicosatrienoic acids and reduced soluble epoxide hydrolase expression in the preeclamptic placenta.
Dalle Vedove F; Fava C; Jiang H; Zanconato G; Quilley J; Brunelli M; Guglielmi V; Vattemi G; Minuz P
J Hypertens; 2016 Jul; 34(7):1364-70. PubMed ID: 27115337
[TBL] [Abstract][Full Text] [Related]
10. Soluble Epoxide Hydrolase as an Important Player in Intestinal Cell Differentiation.
Cizkova K; Koubova K; Foltynkova T; Jiravova J; Tauber Z
Cells Tissues Organs; 2020; 209(4-6):177-188. PubMed ID: 33588415
[TBL] [Abstract][Full Text] [Related]
11. 14,15-Dihydroxyeicosatrienoic acid activates peroxisome proliferator-activated receptor-alpha.
Fang X; Hu S; Xu B; Snyder GD; Harmon S; Yao J; Liu Y; Sangras B; Falck JR; Weintraub NL; Spector AA
Am J Physiol Heart Circ Physiol; 2006 Jan; 290(1):H55-63. PubMed ID: 16113065
[TBL] [Abstract][Full Text] [Related]
12. Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice.
Deng Y; Edin ML; Theken KN; Schuck RN; Flake GP; Kannon MA; DeGraff LM; Lih FB; Foley J; Bradbury JA; Graves JP; Tomer KB; Falck JR; Zeldin DC; Lee CR
FASEB J; 2011 Feb; 25(2):703-13. PubMed ID: 21059750
[TBL] [Abstract][Full Text] [Related]
13. Fibrates Affect Levels of Phosphorylated p38 in Intestinal Cells in a Differentiation-Dependent Manner.
Cizkova K; Tauber Z
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175404
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy.
Kim J; Yoon SP; Toews ML; Imig JD; Hwang SH; Hammock BD; Padanilam BJ
Am J Physiol Renal Physiol; 2015 Jan; 308(2):F131-9. PubMed ID: 25377915
[TBL] [Abstract][Full Text] [Related]
15. Role of cytochrome P450-epoxygenase and soluble epoxide hydrolase in the regulation of vascular response.
Nayeem MA; Geldenhuys WJ; Hanif A
Adv Pharmacol; 2023; 97():37-131. PubMed ID: 37236764
[TBL] [Abstract][Full Text] [Related]
16. The factor in EDHF: Cytochrome P450 derived lipid mediators and vascular signaling.
Fleming I
Vascul Pharmacol; 2016 Nov; 86():31-40. PubMed ID: 26975734
[TBL] [Abstract][Full Text] [Related]
17. CYP2C8 Is a Novel Target of Peroxisome Proliferator-Activated Receptor α in Human Liver.
Makia NL; Goldstein JA
Mol Pharmacol; 2016 Jan; 89(1):154-64. PubMed ID: 26467040
[TBL] [Abstract][Full Text] [Related]
18. Sex- and isoform-specific mechanism of neuroprotection by transgenic expression of P450 epoxygenase in vascular endothelium.
Jia J; Davis CM; Zhang W; Edin ML; Jouihan S; Jia T; Bradbury JA; Graves JP; DeGraff LM; Lee CR; Ronnekleiv O; Wang R; Xu Y; Zeldin DC; Alkayed NJ
Exp Neurol; 2016 May; 279():75-85. PubMed ID: 26902473
[TBL] [Abstract][Full Text] [Related]
19. Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases.
Zordoky BN; El-Kadi AO
Pharmacol Ther; 2010 Mar; 125(3):446-63. PubMed ID: 20093140
[TBL] [Abstract][Full Text] [Related]
20. Influence of inflammation on cardiovascular protective effects of cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids.
Shahabi P; Siest G; Visvikis-siest S
Drug Metab Rev; 2014 Feb; 46(1):33-56. PubMed ID: 24040964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
